Wall Street analysts expect Moderna (MRNA) to post quarterly loss of $2.92 per share in its upcoming report, which indicates a year-over-year increase of 4.9%. Revenues are expected to be $126.98 ...

HHS Announces Plans to Pay Moderna $176 Million for mRNA Flu Vaccine By Stephanie Brown HealthDay Reporter FRIDAY, April 25, 2025 (HealthDay News) -- On Tuesday, the U.S. Department of Health and ...

Kennedy won Senate confirmation to his job, in part, by promising not to change the nation’s vaccine schedule. Since taking ...

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an ...

Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced ...

In the latest trading session, Moderna (MRNA) closed at $27.19, marking a -0.75% move from the previous day. This change lagged the S&P 500's 0.74% gain on the day. On the other hand, the Dow ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

BofA lowered the firm’s price target on Moderna (MRNA) to $26 from $32 and keeps an Underperform rating on the shares. For 2025, the firm’s ...